Scrip
27 November 2009
Simon Varcoe
An extension to Merck & Co and Idera Pharmaceuticals' toll-like receptor (TLR) research agreement failed to stop the latter company's share price from falling on November 25th after Novartis terminated its asthma and allergy research deal.
Novartis paid Idera $4 million up front in May...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
